Arkolith/Insider Trading/AKTS/Form 4

Nodelman Oleg

DirectorAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jan 12, 2026
Net Buying
Open-Market Buys
$40.0M
Open-Market Sells
$0
Net Open-Market Flow
$40.0M
Transactions
12
5 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Buy(P)2.1M$18.00$37.4M4.3M
Jan 12, 2026Conversion(C)129K——129K
Jan 12, 2026Conversion(C)203K——203K
Jan 12, 2026Conversion(C)2.3M——2.3M
Jan 12, 2026Buy(P)144K$18.00$2.6M347K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)9.9M——0
Jan 12, 2026Conversion(C)997K——0
Jan 12, 2026Conversion(C)489K——0
Jan 12, 2026Conversion(C)2.4M——0
Jan 12, 2026Conversion(C)965K——965K
Jan 12, 2026Conversion(C)86K——86K
Jan 12, 2026Conversion(C)103K——0

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000935836-26-000031) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML